Ginger-Derived Nanoparticles Deliver a VEGFA-Targeting DNAzyme in Experimental Retinopathy
Published in Drugs development & discovery, Journals, Nanomedicine.
A study published in the International Journal of Nanomedicine on October 2, 2026 investigates ginger-derived nanoparticles as carriers for a DNAzyme designed to target VEGFA messenger RNA in experimental diabetic retinopathy.
Wang and colleagues report uptake by retinal microvascular endothelial cells, with reduced migration and tube formation under high-glucose laboratory conditions. In diabetic mice, the formulation prolonged the ocular signal from a labeled DNAzyme and reduced retinal VEGFA messenger RNA for up to two weeks after a single injection.
The researchers also observed changes in inflammatory markers. These findings support a preclinical delivery concept; they do not establish restored vision, durable treatment benefit or effectiveness in people.
The authors identify further needs, including dose-matched controls, direct retinal vascular and functional measurements, pharmacokinetic characterization and thorough ocular safety assessment.
Editorial perspective: plant-derived particles may combine delivery functions with biological activity. The experimental formulation is distinct from eating ginger, and its potential requires further testing.
Source: Wang T et al., Ginger-Derived Nanoparticles Deliver a VEGFA-Targeting DNAzyme and Modulate Retinal VEGFA Expression and Inflammatory Markers in Experimental Diabetic Retinopathy, October 2, 2026.